Cargando…
VEGF-A, VEGF-C, VEGF-R2, EGFR and HER2 in serum plus EGFR in tissue of patients with triple-negative breast cancer
Autores principales: | Iosifidou, R, Galaktidou, G, Ananiadis, A, Bladika, N, Patakiouta, F, Bousoulegas, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284899/ http://dx.doi.org/10.1186/bcr2296 |
Ejemplares similares
-
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008) -
EGFR, VEGF, and angiogenesis promote the development of lipoma in the oral cavity
por: da Silva, Weslay Rodrigues, et al.
Publicado: (2023) -
First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
por: Hafner, Susanne
Publicado: (2021) -
Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014) -
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)